Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

TAPS technology has been optimised for mapping DNA methylation on circulating cell-free DNA.

A study led by Chunxiao Song (Ludwig Institute for Cancer Research) and Shivan Sivakumar (Department of Oncology and Oxford University Hospitals Foundation NHS Trust) optimised the TAPS technology developed in Chunxiao’s lab for the mapping of DNA methylation for use on cell-free DNA (cfDNA). Such circulating cfDNA, a tiny proportion of which is shed by tumours in people with cancer, is the focus of efforts to develop liquid biopsies for early cancer detection, most of which have focused on the detection of mutations. Knowing the methylation state of cfDNA can, however, provide critical information unavailable in the DNA sequence alone, such as the likely location of a tumour.

The researchers reported in a paper in Science Advances their use of the optimised TAPS—named cfTAPS—on 85 samples from patients with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC) and noncancer controls, showing that they could generate the most comprehensive cfDNA methylome to date using just 10 nanograms of cfDNA. They demonstrated that cfTAPS provides multimodal information about cfDNA, including its methylation patterns, the tissue from which it originated and DNA fragmentation. The integrated analysis of these epigenetic and genetic features enabled accurate identification of early HCC and PDAC.

Similar stories

National clinical study launched to test new technologies for detecting liver cancer

The SELINA study will recruit patients with early liver cancers as part of the DeLIVER programme aiming to detect liver cancer earlier.

First major UK prospective study for liver cancer underway

The Pearl clinical study will recruit 3000 patients with high-risk conditions for liver cancer with the aim of detecting liver cancer earlier as part of the Cancer Research UK-funded DeLIVER programme.